IDEAYA Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
IDEAYA Biosciences, Inc. (IDYA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $1.90 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-04
- IDEAYA Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $1.10M, a 450.00% increase year-over-year.
- IDEAYA Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $800.00K, a 33.33% increase year-over-year.
- IDEAYA Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $1.60M, a 0.00% change year-over-year.
- IDEAYA Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $100.00K, a 97.06% decline year-over-year.
- IDEAYA Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $2.50M, a 92.19% decline from fiscal 2024.
- IDEAYA Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $32.00M, a 89.35% increase from fiscal 2023.
- IDEAYA Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $16.90M, a 838.89% increase from fiscal 2022.
- IDEAYA Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $1.80M, a 48.57% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $1.90M 10-Q · filed 2026-08-04 | $3.50M derived: sum of 3 quarters · filed 2026-08-04 | $3.60M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $800.00K 10-Q · filed 2026-05-05 | $2.40M derived: sum of 2 quarters · filed 2026-05-05 | $2.50M derived: sum of 3 quarters · filed 2026-05-05 | $2.70M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $1.70M derived: sum of 2 quarters · filed 2026-02-17 | $1.90M derived: sum of 3 quarters · filed 2026-08-04 | $2.50M 10-K · filed 2026-02-17 |
| 2025-09-30 | $100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $300.00K derived: sum of 2 quarters · filed 2026-08-04 | $900.00K 10-Q · filed 2025-11-04 | $2.50M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $200.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $800.00K 10-Q · filed 2026-08-04 | $2.40M derived: sum of 3 quarters · filed 2026-08-04 | $5.80M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $600.00K 10-Q · filed 2026-05-05 | $2.20M derived: sum of 2 quarters · filed 2026-05-05 | $5.60M derived: sum of 3 quarters · filed 2026-05-05 | $18.10M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $5.00M derived: sum of 2 quarters · filed 2026-02-17 | $17.50M derived: sum of 3 quarters · filed 2026-02-17 | $32.00M 10-K · filed 2026-02-17 |
| 2024-09-30 | $3.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $15.90M derived: sum of 2 quarters · filed 2025-11-04 | $30.40M 10-Q · filed 2025-11-04 | $43.30M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $12.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $27.00M 10-Q · filed 2025-08-05 | $39.90M derived: sum of 3 quarters · filed 2026-02-17 | $42.00M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $14.50M 10-Q · filed 2025-05-06 | $27.40M derived: sum of 2 quarters · filed 2026-02-17 | $29.50M derived: sum of 3 quarters · filed 2026-02-17 | $30.80M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $12.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $15.00M derived: sum of 2 quarters · filed 2026-02-17 | $16.30M derived: sum of 3 quarters · filed 2026-02-17 | $16.90M 10-K · filed 2026-02-17 |
| 2023-09-30 | $2.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $3.40M derived: sum of 2 quarters · filed 2024-11-04 | $4.00M 10-Q · filed 2024-11-04 | $4.60M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-06-30 | $1.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $1.90M 10-Q · filed 2024-08-06 | $2.50M derived: sum of 3 quarters · filed 2025-02-18 | $2.70M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-03-31 | $600.00K 10-Q · filed 2024-05-07 | $1.20M derived: sum of 2 quarters · filed 2025-02-18 | $1.40M derived: sum of 3 quarters · filed 2025-02-18 | $1.50M derived: sum of 4 quarters · filed 2025-02-18 |
| 2022-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $800.00K derived: sum of 2 quarters · filed 2025-02-18 | $900.00K derived: sum of 3 quarters · filed 2025-02-18 | $1.80M 10-K · filed 2025-02-18 |
| 2022-09-30 | $200.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $300.00K derived: sum of 2 quarters · filed 2023-11-07 | $1.20M 10-Q · filed 2023-11-07 | $2.30M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $1.00M 10-Q · filed 2023-08-10 | $2.10M derived: sum of 3 quarters · filed 2023-08-10 | $3.60M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $900.00K 10-Q · filed 2023-05-09 | $2.00M derived: sum of 2 quarters · filed 2023-05-09 | $3.50M derived: sum of 3 quarters · filed 2023-05-09 | $4.10M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $2.60M derived: sum of 2 quarters · filed 2023-03-07 | $3.20M derived: sum of 3 quarters · filed 2023-03-07 | $3.50M 10-K · filed 2023-03-07 |
| 2021-09-30 | $1.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $2.10M derived: sum of 2 quarters · filed 2022-11-08 | $2.40M 10-Q · filed 2022-11-08 | $2.70M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $600.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $900.00K 10-Q · filed 2022-08-15 | $1.20M derived: sum of 3 quarters · filed 2022-08-15 | $1.60M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $300.00K 10-Q · filed 2022-05-10 | $600.00K derived: sum of 2 quarters · filed 2022-05-10 | $1.00M derived: sum of 3 quarters · filed 2022-05-10 | |
| 2020-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $700.00K derived: sum of 2 quarters · filed 2022-03-18 | $1.70M 10-K · filed 2022-03-18 | |
| 2020-09-30 | $400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $1.40M 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | $1.00M 10-Q · filed 2021-08-10 | |||
| 2019-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | $300.00K derived: sum of 2 quarters · filed 2021-03-23 | $800.00K 10-K · filed 2021-03-23 | |
| 2019-09-30 | $200.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $700.00K 10-Q · filed 2019-11-13 | ||
| 2019-06-30 | $500.00K 10-Q · filed 2019-08-12 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-24 | $0.00 derived: sum of 2 quarters · filed 2020-03-24 | $100.00K 10-K · filed 2020-03-24 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $100.00K 10-Q · filed 2019-11-13 | ||
| 2018-06-30 | $100.00K 10-Q · filed 2019-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |